Shyam Kottilil is a Professor of Medicine at the Division of Clinical Care and Research at the Institute of Human Virology (IHV). He is also the Associate Chief of the Division of Clinical Care and Research and Co-director of the Clinical Trials Unit at the Institute. Prior to his appointment at IHV in 2014, Dr. Kottilil was at the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases at the National Institutes of Health (Bethesda, USA). He received his MD from the Government Medical College (Trichur, India); he performed his residency in Internal Medicine at Brown University School of Medicine (Providence, RI, USA) and a fellowship in Infectious Diseases from the National Institute of Allergy and Infectious Diseases, NIH (Bethesda, USA). He received his Ph.D from Memorial University of Newfoundland (Canada), where he studied the role of cytotoxic cells in HIV infection. He joined the Immunopathogenesis Section of the NIAID, NIH (Bethesda, USA) in the year 2000, as a clinical fellow where he continues to study immunopathogenesis of Human Immunodeficiency virus and Hepatitis C viruses with Dr. Anthony S Fauci.
In 2009, Dr. Kottilil was appointed as the Scientific Director of the District of Columbia Program fro AIDS Progress (DC-PFAP) to lead a clinical and translational program studying HCV and HBV as opportunistic pathogens of HIV infection. Since then, he has served as the principal investigator for several pivotal clinical trials including SPARE, SYNERY and ERADICATE. He continues to be the Scientific Director of the DC PFAP and Director of the Hepatitis Program at the Veterans Affairs Medical Center at Baltimore, MD.
His current research objectives include: (1) design of novel therapeutic strategies to cure HCV and HBV (2) determination of clinical and biological correlates of anti-HCV and HBV treatment response; and (3) identification of biomarkers of disease progression, therapeutic response and tumorigenesis (hepatoma) using an integrated database approach (DNA, RNA, protein and function). In order to achieve the above goals, he conducts clinical trials employing Phase I, Phase II, and Phase III methodologies.